Gino In

Associate Professor of Clinical Medicine

Image of Gino In
Is this your profile? Click to edit

Overview

Gino K. In, MD, MPH, is a medical oncologist who specializes in solid tumor and cutaneous oncology. He completed his fellowship training in hematology and oncology at the University of Southern California, Keck School of Medicine, where he was the chief medical oncology fellow. He subsequently joined the USC Norris Comprehensive Cancer Center, and now serves as Assistant Professor of Clinical Medicine in the Division of Oncology, and Assistant Professor of Dermatology. Dr. In’s research focus includes the multi-disciplinary management of melanoma and other skin cancers, including cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma. He has a specific interest in non-UV related melanoma subtypes and intratumoral therapies. Dr. In is the lead primary investigator for cutaneous oncology clinical trials at USC, including studies through the National Cancer Institute, California Cancer Consortium, and Southwest Oncology Group.

Awards

  • University of Southern California: Chief Medical Oncology Fellow

Education and Training

  • University of Southern California, Los Angeles, CA — Fellowship — 2016 — Hematology/Oncology
  • SUNY Downstate Medical Center, Brooklyn, NY — Residency — 2011 — Internal Medicine
  • SUNY Downstate Medical Center, Brooklyn, NY — Internship — 2010
  • Ross University, North Brunswick Township, NJ — MD — 2010 — Medicine
  • Emory University, Atlanta, GA — MPH — 2006 — Environmental/Occupational Health
  • Emory University, Atlanta, GA — BS — 2002

Research Keywords

  • Medical Oncology
  • Skin Cancer
  • Melanoma
  • Acral Lentiginous Melanoma
  • Uveal Melanoma
  • Mucosal Melanoma
  • Squamous Cell Carcinoma
  • Basal Cell Carcinoma
  • Merkel Cell Carcinoma
  • Dermatofibrosarcoma Protuberans
  • Porocarcinoma

Publications

  • Acral lentiginous melanoma. Part II. Staging, surgical management, the role of systemic therapy, shortcomings, and future directions. J Am Acad Dermatol. 2026 02; 94(2):435-446.. View in PubMed
  • Social health, activity behaviors, and quality of life among young adult cancer survivors: Protocol for a prospective observational study. PLoS One. 2024; 19(11):e0309924.. View in PubMed
  • Comparative effectiveness among BRAF plus MEK inhibitors for patients with BRAF V600-mutant melanoma. ESMO Real World Data Digit Oncol. 2024 Dec; 6:100071.. View in PubMed
  • A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma. Gynecol Oncol. 2024 09; 188:13-21.. View in PubMed
  • Influence of Anatomic Locations of T1b Melanomas and Patient Age on Outcomes. J Drugs Dermatol. 2024 May 01; 23(5):306-310.. View in PubMed
  • Clinicopathologic comparison of basal cell carcinoma among a diverse patient population in Los Angeles County. Skin Health Dis. 2024 Aug; 4(4):e379.. View in PubMed
  • Cutaneous adverse effects induced by tebentafusp in patients with metastatic uveal melanoma: a case series and treatment insights. Clin Exp Dermatol. 2024 Mar 21; 49(4):392-394.. View in PubMed
  • Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors. Cell Death Dis. 2024 02 14; 15(2):140.. View in PubMed
  • Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases. NPJ Precis Oncol. 2023 Nov 14; 7(1):120.. View in PubMed
  • Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus. Front Endocrinol (Lausanne). 2023; 14:1242830.. View in PubMed